We are live on ! Find out more
IHM

Iguana Healthcare Management Portfolio holdings

AUM $152M
1-Year Est. Return 48.74%
This Fund
S&P 500
This Quarter Est. Return
-5.32%
1 Year Est. Return
+48.74%
3 Year Est. Return
+142.13%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$167M
AUM Growth
-$394M
Cap. Flow
-$366M
Cap. Flow %
-218.91%
Top 10 Hldgs %
44.66%
Holding
98
New
19
Increased
–
Reduced
39
Closed
38

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$4.56M
2
WBA
Walgreens Boots Alliance
WBA
+$2.89M
3
AGN
Allergan plc
AGN
+$2.59M
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$2.02M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.9M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$20.2M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$17M
3
PFE icon
Pfizer
PFE
+$16.9M
4
ZBH icon
Zimmer Biomet
ZBH
+$13.2M
5
SHPG
Shire pic
SHPG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 75.65%
2 Energy 0.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DPLO
51
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$630K 0.38%
+50,000
New +$931K
AXDX
52
DELISTED
Accelerate Diagnostics
AXDX
$623K 0.37%
3,000
-12,000
-80% -$2.85M
MYOV
53
DELISTED
Myovant Sciences Ltd.
MYOV
$622K 0.37%
+50,000
New +$579K
MDRX
54
DELISTED
Veradigm Inc. Common Stock
MDRX
$613K 0.37%
60,000
-390,000
-87% -$4.45M
XBI icon
55
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$592K 0.35%
+10,000
New +$617K
PACB icon
56
Pacific Biosciences
PACB
$354M
$570K 0.34%
150,000
-150,000
-50% -$1.09M
ADMA icon
57
ADMA Biologics
ADMA
$2.21B
$512K 0.31%
100,000
-200,000
-67% -$1.15M
ADAP
58
DELISTED
Adaptimmune Therapeutics
ADAP
$405K 0.24%
100,000
-200,000
-67% -$959K
OMED
59
CALL
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$386K 0.23%
50,000
– –
TNDM icon
60
Tandem Diabetes Care
TNDM
$1.62B
$161K 0.1%
7,500
-29,500
-80% -$1.13M
ACAD icon
61
Acadia Pharmaceuticals
ACAD
$5.05B
– –
-50,000
Closed -$1.59M
ACHC icon
62
Acadia Healthcare
ACHC
$2.93B
– –
-70,000
Closed -$3.47M
ALNY icon
63
Alnylam Pharmaceuticals
ALNY
$29.7B
– –
-150,000
Closed -$10.2M
AVDL
64
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-400,000
Closed -$4.96M
BIIB icon
65
CALL
Biogen
BIIB
$30B
– –
-25,000
Closed -$7.83M
BMY icon
66
Bristol-Myers Squibb
BMY
$130B
– –
-130,000
Closed -$7.01M
ESPR
67
DELISTED
Esperion Therapeutics
ESPR
– –
-80,000
Closed -$1.11M
ESPR
68
PUT
DELISTED
Esperion Therapeutics
ESPR
– –
-100,000
Closed -$1.39M
EXEL icon
69
Exelixis
EXEL
$12.6B
– –
-700,000
Closed -$8.95M
GILD icon
70
CALL
Gilead Sciences
GILD
$168B
– –
-30,000
Closed -$2.37M
IONS icon
71
Ionis Pharmaceuticals
IONS
$9.24B
– –
-100,000
Closed -$3.66M
LLY icon
72
CALL
Eli Lilly
LLY
$1.07T
– –
-75,000
Closed -$6.02M
LITS
73
Lite Strategy Inc
LITS
$30.7M
– –
-30,000
Closed -$1.06M
MGNX icon
74
MacroGenics
MGNX
$252M
– –
-80,000
Closed -$2.39M
OPCH icon
75
Option Care Health
OPCH
$3.54B
– –
-375,000
Closed -$4.34M
1 2
3
4

Similar funds

HWP
Hefty Wealth Partners Auburn, Indiana $155M AUM 7.56% 1-Year Est. Return
PAM
PineView Asset Management Greenwich, Connecticut $166M AUM 27.74% 1-Year Est. Return
USG2
Union Square GP 2008 New York $172M AUM
LCM
Lee Capital Management New York $132M AUM 21% 1-Year Est. Return
FPF
FNY Partners Fund New York $185M AUM 32.59% 1-Year Est. Return
FIAS
FinTrust Investment Advisory Services Greenville, South Carolina $109M AUM
CII
Chapter IV Investors Charlotte, North Carolina $109M AUM 9.21% 1-Year Est. Return
OPWM
Oak Point Wealth Management Portage, Michigan $98M AUM

Iguana Healthcare Management's Q4 2016 Portfolio in Review

As of Q4 2016, Iguana Healthcare Management held 98 positions worth $167M, down 70% from $561M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Iguana Healthcare Management withdrew a net $366M in Q4 2016, closing 38 positions and reducing 39 holdings. Its most notable exit was Pfizer, an estimated $16.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 73% a quarter earlier, followed by Energy.

Against the trend, Iguana Healthcare Management opened a new position in Abbott worth $4.42M.

  • Iguana Healthcare Management's largest Q4 2016 buy was Abbott: 115,000 shares worth $4.42M.
  • Iguana Healthcare Management's biggest Q4 2016 reduction was Clovis Oncology, Inc., cutting an estimated $20.2M.
  • Iguana Healthcare Management fully exited Pfizer in Q4 2016, selling an estimated $16.9M.
  • Iguana Healthcare Management's ten largest holdings make up 45% of its $167M portfolio in Q4 2016.
  • Iguana Healthcare Management opened 19 new positions and closed 38 in Q4 2016.
  • Iguana Healthcare Management's portfolio value fell 70% quarter-over-quarter to $167M.

Based on Iguana Healthcare Management's 13F filing for Q4 2016, filed 14 Feb 2017.